Opin vísindi

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor


Title: Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
Author: Dowsett, Joseph
Ferkingstad, Egil   orcid.org/0000-0001-8090-7988
Rasmussen, Line Jee Hartmann
Thørner, Lise Wegner
Magnússon, Magnús Karl
Sugden, Karen
Þorleifsson, Guðmar
Frigge, Mike
Burgdorf, Kristoffer Sølvsten
Ostrowski, Sisse Rye
... 19 more authors Show all authors
Date: 2021-06-02
Language: English
Scope: 1
University/Institute: Landspitali - The National University Hospital of Iceland
Department: Faculty of Medicine
Office of Division of Diagnostic and Support Services
Series: Communications Biology; 4(1)
ISSN: 2399-3642
DOI: https://doi.org/10.1038/s42003-021-02144-8
Subject: Bólgur; Erfðafræði; Lífmerki; Lífmerki; Litningar; Biomarkers; Chromosome mapping; Inflammation mediators; Multifactoral inheritance; Genome-wide association study; polymorphism, single nucleotide; Quantitative trait; Heritable; Receptors; Urokinase Plasminogen Activator; Cohort studies; C-Reactive Protein; Agricultural and Biological Sciences (all); Biochemistry, Genetics and Molecular Biology (all); Medicine (miscellaneous)
URI: https://hdl.handle.net/20.500.11815/3123

Show full item record

Citation:

Dowsett , J , Ferkingstad , E , Rasmussen , L J H , Thørner , L W , Magnússon , M K , Sugden , K , Þorleifsson , G , Frigge , M , Burgdorf , K S , Ostrowski , S R , Sørensen , E , Erikstrup , C , Pedersen , O B , Hansen , T F , Banasik , K , Brunak , S , Tragante , V , Lund , S H , Stefánsdóttir , L , Gunnarson , B , Poulton , R , Arseneault , L , Caspi , A , Moffitt , T E , Gudbjartsson , D F , Eugen-Olsen , J , Stefánsson , H , Stefánsson , K & Ullum , H 2021 , ' Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor ' , Communications Biology , vol. 4 , no. 1 , pp. 655 . https://doi.org/10.1038/s42003-021-02144-8

Abstract:

Soluble urokinase-type plasminogen activator receptor (suPAR) is a chronic inflammation marker associated with the development of a range of diseases, including cancer and cardiovascular disease. The genetics of suPAR remain unexplored but may shed light on the biology of the marker and its connection to outcomes. We report a heritability estimate of 60% for the variation in suPAR and performed a genome-wide association meta-analysis on suPAR levels measured in Iceland (N = 35,559) and in Denmark (N = 12,177). We identified 13 independently genome-wide significant sequence variants associated with suPAR across 11 distinct loci. Associated variants were found in and around genes encoding uPAR (PLAUR), its ligand uPA (PLAU), the kidney-disease-associated gene PLA2R1 as well as genes with relations to glycosylation, glycoprotein biosynthesis, and the immune response. These findings provide new insight into the causes of variation in suPAR plasma levels, which may clarify suPAR's potential role in associated diseases, as well as the underlying mechanisms that give suPAR its prognostic value as a unique marker of chronic inflammation.

Description:

This study was supported by the Danish Council for Independent Research (09-069412 and 0602-02634B), Aase og Ejnar Danielsens Fond, AP Møller Fonden, and the Danish Regions (02/2611). The DBDS genetic infrastructure was supported by the Novo Nordic Foundation (NNF17OC0027594). S.B. reports grants from Innovation Fund Denmark, grants from Novo Nordisk Foundation during the conduct of the study; and personal fees from Intomics A/S and Proscion A/S, outside the submitted work. S.B. and K.B. report on behalf of Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, that the following grants supported the study: The Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594) and The Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115881 (RHAPSODY). L.J.H.R. is supported by an international postdoctoral fellowship from the Lundbeck Foundation (grant no. R288-2018-380). The E-Risk Study is funded by the Medical Research Council (UKMRC grant G1002190). Additional support was provided by the National Institute of Child Health and Human Development (grant HD077482) and by the Jacobs Foundation. The authors are grateful to the Study members and their families for their participation. Our thanks CACI, Inc., and to members of the E-Risk team for their dedication, hard work, and insights. We thank the Dunedin Study members, Unit research staff, and Study founder Phil Silva. This research was supported by US-National Institute on Aging grants AG032282 and UK Medical Research Council grant MR/P005918/1. The Dunedin Multidisciplinary Health and Development Research Unit is supported by the New Zealand Health Research Council Programme Grant (16-604), and the New Zealand Ministry of Business, Innovation, and Employment (MBIE).

Files in this item

This item appears in the following Collection(s)